Enjoy complimentary customisation on priority with our Enterprise License!
The global allergy rhinitis drugs market size is estimated to grow by USD 3.17 billion at a CAGR of 3.92% between 2023 and 2028. Technological advances in allergy rhinitis diagnostics have a favorable influence on the market growth. The significant challenge faced by the market is the unclear pathogenesis and prognosis of various allergy indications. The unclear pathogenesis of these allergies leads to a poor diagnosis. Currently, blood tests, skin tests, and patch tests are being used to diagnose allergies. However, recent advances are helping to increase the number of patients being diagnosed in the early stages of allergy and, hence, making treatment more effective.
For instance, Siemens Healthcare manufactured the IMMULITE 2000 XPi Immunoassay system, which is being used for the diagnosis of various medical conditions such as allergy, anemia, autoimmune disorders, bone metabolism, diabetes, inflammation, various oncology indications, reproductive endocrinology, and thyroid. These advances are expected to lead to the identification of new allergens, which will lead to the development of better allergy rhinitis drugs, thus resulting in the growth of the market during the forecast period.
To learn more about this report, Request Free Sample
This market report extensively covers market segmentation by distribution channel (offline and online), product (antihistamines, intranasal corticosteroids, immunotherapies, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)).
In the corporate world, allergic rhinitis, a common respiratory disease caused by allergens such as pollen, has become a significant healthcare concern for workers. Allergic reactions, characterized by sneezing, swelling, and watery eyes, can significantly impact productivity and quality of life. Diagnostic methods are essential to identify the root cause of allergic rhinitis, leading to various therapies and medicines. Pharmacological approaches include nasal corticosteroids and biologics, which help reduce inflammation and alleviate symptoms. Personalized medicine, considering an individual's genetic makeup, is gaining popularity in the treatment of allergic rhinitis. Medical technology and drug delivery systems, such as nasal sprays and inhalers, have revolutionized the way these medications are administered. Cervical injuries from vehicle accidents can also lead to cervical spondylosis, causing neck pain and discomfort. In such cases, non-pharmacological approaches, like physical therapy and chiropractic care, can be beneficial. Overall, the allergic rhinitis drugs market is witnessing significant growth due to the increasing prevalence of allergic reactions and advancements in medical technology. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
The increasing prevalence of allergy rhinitis is notably driving the market growth. Allergic rhinitis, a non-infectious inflammatory condition characterized by sneezing, rhinorrhea, nasal congestion, and nasal pruritus, affects a significant portion of the global population. According to recent studies, in the UK, approximately one in five individuals experience this healthcare disease. Seasonal allergic rhinitis, often linked to allergens such as pollen, is most prevalent among children, while chronic rhinitis is more common in adults due to occupational allergens, cervical injuries from vehicle accidents, or tobacco use. The allergic response involves an inflammatory process triggered by sensitivities to various allergens, including animal dander, dust, and air pollution. This response results in the release of cytokines and interleukins, leading to symptoms such as swelling, watery eyes, and sneezing.
Further, pharmacological approaches to managing allergic rhinitis include over-the-counter medications like antihistamines and decongestants, as well as prescription therapies such as corticosteroids and immunotherapy. Immunomodulatory peptide drugs are also being researched as potential treatments. It is essential to note that while these medicines offer relief, they may come with side effects. Therefore, accurate diagnostic methods are crucial in determining the most effective treatment for each patient. In addition, addressing the root causes, such as cervical spondylosis or climate change, may also contribute to managing allergic rhinitis. This increase in the worldwide incidence of allergy rhinitis is expected to drive the growth of the market during the forecast period.
Increase in R&D of new therapies is an emerging trend shaping market growth. Allergic rhinitis, a healthcare disease characterized by sneezing, swelling, watery eyes, and nasal congestion, is a global concern with increasing prevalence. This inflammatory response to allergens, such as pollen, tobacco, animal dander, or dust, can lead to more severe respiratory diseases like asthma. Corporate workers and individuals with cervical injuries from vehicle accidents are particularly susceptible due to occupational allergens and stress. Researchers are exploring new strategies for medicines to manage allergic rhinitis. For instance, an immunomodulatory peptide drug discovered at Aarhus University blocks the immune effect behind allergic reactions by inactivating specific antibodies and removing immunoglobulin E molecules. This breakthrough offers new possibilities for pharmacological approaches. Diagnostic methods are essential for identifying allergic rhinitis types, including seasonal, perennial, and occupational. Over-the-counter medications like antihistamines, corticosteroids, and decongestants provide temporary relief, but long-term use may cause side effects.
Moreover, immunotherapy, another therapeutic approach, modifies the immune system's response to allergens. Air pollution and climate change exacerbate allergic rhinitis, necessitating ongoing research and innovative therapies. Cytokines and interleukins play crucial roles in the inflammatory response. Understanding their mechanisms can lead to more effective medicines. Inflammatory response markers, such as sneezing and swelling, can indicate the need for intervention. Pharmacological approaches, including antihistamines, corticosteroids, and immunotherapy, are essential for managing allergic rhinitis. However, ongoing research into immunomodulatory peptide drugs offers new hope for more effective and targeted treatments. Therefore, patients are inclined toward over-the-counter drugs. Therefore, such factors foster the growth of the market during the forecast period.
Increased use of complementary and alternative medicine is a significant challenge hindering market growth. Allergic rhinitis, a healthcare disease characterized by an inflammatory response to allergens, poses a significant challenge to the global market for medicines and therapies. While traditional pharmacological approaches, such as antihistamines, corticosteroids, and decongestants, remain prevalent, an increasing number of patients, particularly corporate workers and those suffering from cervical injuries or vehicle accidents, are turning to complementary and alternative medicines (CAM). These include immunomodulatory peptide drugs like spirulina, butterbur, and phototherapy. The popularity of CAM is driven by factors such as safety, convenience, and affordability.
However, patients with seasonal allergic rhinitis, perennial allergic rhinitis, and occupational allergic rhinitis, triggered by allergens such as pollen, tobacco, animal dander, dust, and climate change, are increasingly seeking effective treatments. Diagnostic methods and interleukins play a crucial role in understanding the inflammatory response. Over-the-counter medications and side effects are also relevant considerations. Immunotherapy, a pharmacological approach, offers long-term benefits. Oral, nasal, and other forms of medications are commonly used to alleviate symptoms such as sneezing, swelling, and watery eyes. Therefore, the increased use of complementary and alternative medicine will negatively impact the growth of the market during the forecast period.
The market report includes the adoption lifecycle of the market research and growth, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.
Market Customer Landscape
The market share growth by the offline segment will be significant during the forecast period. The offline segment of allergy rhinitis drugs by retail pharmacies is a critical aspect of ensuring that patients have convenient access to the medications they need for managing allergy conditions. Retail pharmacies, including chain pharmacies, independent pharmacies, and online pharmacies, play a significant role in the distribution process.
Get a glance at the market contribution of various segments Download PDF Sample
The offline segment was the largest and was valued at USD 9.96 billion in 2018. Offline segments maintain records of dispensed medications and patient information. This documentation is essential for record-keeping, patient history, and potential future interactions. In addition to that, retail pharmacies are often located in easily accessible locations, including urban and suburban areas. This accessibility ensures that patients can obtain their respiratory medications conveniently, even between healthcare provider visits. Moreover, pharmacists in retail settings offer consultations and recommendations for over-the-counter products to manage mild allergy symptoms, enhancing the overall care experience for patients. Thus, factors such as the presence of pharmacist consultations and convenient access to medications will contribute to the growth of the offline segment, which will strengthen the market during the forecast period.
Antihistamines are a pharmaceutical class of drugs that act to treat histamine-mediated conditions. The antihistamines segment is expected to witness growth during the forecast period. The major growth driver is the increasing use of antihistamines as a first-line approach to prevent or relieve the symptoms of allergic rhinitis. Most of the guidelines, including the Allergy Rhinitis and its Impact on Asthma Guidelines published in 2016, recommend the use of oral and intranasal antihistamines as the first approach for managing the symptoms of allergy rhinitis. Moreover, intranasal antihistamines have the ability to deliver a higher concentration of medication to a specific area. Currently, Astelin and Pataday are the two FDA-approved intranasal antihistamine preparations for the treatment of allergy rhinitis. Therefore, the antihistamines segment is expected to grow in the global market during the forecast period.
Intranasal corticosteroid drugs are the most preferred approach after antihistamines for the treatment of allergic rhinitis. One of the major factors that drive the growth of this segment is that intranasal corticosteroids are safe for long-term administration. Another factor is the patient convenience associated with the use of intranasal corticosteroids in the form of a spray, aerosol liquid, or aerosol powder. The market is expected to experience an accelerated growth momentum during the forecast period, owing to the increase in the demand for safe long-term treatments. Hence, more companies are investing in the manufacturing of intranasal corticosteroids. The development of novel corticosteroids is expected to fuel the growth of this segment in allergy rhinitis drugs during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
Asia is estimated to contribute 31% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Another region offering significant growth opportunities to companies is North America. The Allergy Rhinitis Drugs Market in North America is projected to expand significantly due to the rising prevalence of allergy rhinitis in the US and Canada. Non-pharmacological approaches, such as allergen avoidance and saline nasal sprays, are commonly used, but the market for pharmacological treatments is also thriving. Nasal corticosteroids and biologics are among the most effective pharmacological interventions.
Further, personalized medicine, which considers a patient's genetic makeup, is gaining popularity in the development of new treatments. Medical technology, including molecular diagnostics and genetic testing, is advancing, leading to improved drug delivery systems like nasal sprays and inhalers. Technological advancements in treatment outcomes prioritize patient convenience, ensuring continued market growth. Key players in the region, with extensive research and development capabilities, contribute to the market's dominance. The increasing adoption of technologically advanced diagnostic equipment and the high prevalence of various types of allergic diseases, including allergic rhinitis, in the US will further enhance the growth of the market in the region during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
ALK Abello AS - This company offers allergy rhinitis drug such as Subcutaneous allergy immunotherapy (SCIT), Sublingual allergy immunotherapy (SLIT) drops, and SLIT tablets.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.
The market encompasses a range of treatments designed to alleviate the symptoms of allergic rhinitis, a condition characterized by chronic inflammation of the nasal passages and sinuses. Ceramic and aluminum particles, as well as certain chemicals, are used in corporeal therapies, such as ceramic bead implantation and silicone implantation, to stimulate the body's response and improve mucosal function. Intralumenal antigen delivery systems, like those using Vecotec and Dust-Off technology, are utilized to deliver allergens directly to the mucosal surface for desensitization. Medications like antihistamines, corticosteroids, and leukotriene modifiers are commonly prescribed to manage symptoms. Oral and topical decongestants, as well as anticholinergics, are also used to provide relief from nasal congestion and other symptoms. The market for allergy rhinitis treatments is expected to grow significantly due to the increasing prevalence of allergic rhinitis and the development of new and innovative therapies.
Market Scope |
|
Report Coverage |
Details |
Page number |
165 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 3.92% |
Market Growth 2024-2028 |
USD 3.17 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
3.54 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
Asia at 31% |
Key countries |
US, Germany, UK, France, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
ALK Abello AS, Apotex Inc., Bayer AG, Cadila Pharmaceuticals Ltd., Catalent Inc., Dr Reddys Laboratories Ltd., Faes Farma SA, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., HAL Allergy BV, Haleon Plc, Hikma Pharmaceuticals Plc, KYORIN Holdings Inc., Merck and Co. Inc., Mitsubishi Chemical Group Corp., Novartis AG, Sanofi SA, Stallergenes Greer Ltd., Ube Corp., and Viatris Inc. |
Market dynamics |
Parent market growth analysis, Market Forecasting, Market growth inducers and obstacles, market forecast, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.